Abstract
Background
Initiating continuous renal replacement therapy (CRRT) in infants exposes them to the dual hemodynamic challenges of high circuit extracorporeal volumes and potential membrane reactions, in the case of acrylonitrile AN69 membranes. The use of the new Prismaflex HF20 membrane in hemodynamically unstable low-body-weight infants on inotropic support has not been reported.
Treatment
We describe the use of the HF20 (Gambro Lundia AB, Lund, Sweden) membrane in four low-body-weight infants (2.3 to 5.4 kg) with multi-organ dysfunction syndrome who were critically ill in the Pediatric Intensive Care Unit (PICU), hemodynamically unstable, and on inotropes. We were able to achieve target volume loss in all infants without compromising their hemodynamic status. Mean arterial pressures were maintained between 39 and 57 mmHg. The relatively low circuit volume of the HF20 set (60 ml) obviated the need for blood prime in the majority; however, when blood prime was required, there was no adverse reaction with the polyarylethersulfone (PAES) membrane. Solute clearance in these small infants was efficient with correction of metabolic acidosis and electrolyte abnormalities. Excellent circuit lifespan (56.3 ± 32.3 h) was observed.
Conclusions
CRRT using the HF20 membrane is safe and hemodynamically well tolerated in high-risk, unstable low-body-weight infants with cardiac dysfunction on multiple inotropes.
This is a preview of subscription content, log in via an institution to check access.
References
Brophy PD, Mottes TA, Kudelka TL, McBryde KD, Gardner JJ, Maxvold NJ, Bunchman TE (2001) AN-69 membrane reactions are pH-dependent and preventable. Am J Kidney Dis 38:173–178
Hackbarth RM, Eding D, Gianoli Smith C, Koch A, Sanfilippo DJ, Bunchman TE (2005) Zero balance ultrafiltration (Z-BUF) in blood-primed CRRT circuits achieves electrolyte and acid–base homeostasis prior to patient connection. Pediatr Nephrol 20:1328–1333
Sutherland SM, Zappitelli M, Alexander SR, Chua AN, Brophy PD, Bunchman TE, Hackbarth R, Somers MJ, Baum M, Symons JM, Flores FX, Benfield M, Askenazi D, Chand D, Fortenberry JD, Mahan JD, McBryde K, Blowey D, Goldstein SL (2010) Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. Am J Kidney Dis 55:316–325
Rödl S, Marschitz I, Mache CJ, Koestenberger M, Madler G, Zobel G (2011) Continuous renal replacement therapy with Prismaflex HF20 disposable set in children from 4 to 15 kg. ASAIO J 57:451–455
Symons JM, Brophy PD, Gregory MJ, McAfee N, Somers MJ, Bunchman TE, Goldstein SL (2003) Continuous renal replacement therapy in children up to 10 kg. Am J Kidney Dis 41:984–989
Rödl S, Marschitz I, Mache CJ, Koestenberger M, Madler G, Rehak T, Zobel G (2011) One-year safe use of the Prismaflex HF20(®) disposable set in infants in 220 renal replacement treatment sessions. Intensive Care Med 37:884–885
Santiago MJ, López-Herce J (2011) Prismaflex HF20 for continuous renal replacement therapy in critically ill children. Artif Organs 35:1194
Askenazi DJ, Goldstein SL, Koralkar R, Fortenberry J, Baum M, Hackbarth R, Blowey D, Bunchman TE, Brophy PD, Symons J, Chua A, Flores F, Somers MJ (2012) Continuous renal replacement therapy for children ≤10 kg: a report from the prospective pediatric continuous renal replacement therapy registry. J Pediatr. doi:10.1016/j.jpeds.2012.08.044
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, I.D., Ng, KH., Lau, P.YW. et al. Use of HF20 membrane in critically ill unstable low-body-weight infants on inotropic support. Pediatr Nephrol 28, 819–822 (2013). https://doi.org/10.1007/s00467-012-2394-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-012-2394-3